Trump's 200% tariff threat leaves pharma firms scrambling with scenario planning
A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.
You are not logged in so some information on this page has been withheld. To see more, please log in.